Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial.
about
Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infectionsPseudomonas aeruginosa ventilator-associated pneumonia managementAssessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patientsYear in review 2012: Critical Care--respiratory infectionsContinuous infusion of piperacillin/tazobactam in septic critically ill patients--a multicenter propensity matched analysis.Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious DiseasesEmpiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearanceOutcomes in Documented Pseudomonas aeruginosa Bacteremia Treated with Intermittent IV Infusion of Ceftazidime, Meropenem, or Piperacillin-Tazobactam: A Retrospective Study.Continuous beta-lactam infusion in critically ill patients: the clinical evidenceDosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approachContinuous infusion of meropenem in critically ill patients: practical considerations.Overview of progresses in critical care medicine 2012.An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.Management of Pneumonia and Blood Stream Infections with New Antibiotic Adjuvant Entity (Ceftriaxone + Sulbactam + Disodium Edetate)- A Novel Way to Spare Carbapenems.Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.Optimal dosing of antibiotics in critically ill patients by using continuous/extended infusions: a systematic review and meta-analysis.Improved treatment of multidrug-resistant bacterial infections: utility of clinical studies.Extended infusion of beta-lactam antibiotics: optimizing therapy in critically-ill patients in the era of antimicrobial resistance.Quantitative clinical pharmacology practice for optimal use of antibiotics during the neonatal period.Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory.Prolonged versus Intermittent Infusion of β-Lactams for the Treatment of Nosocomial Pneumonia: A Meta-Analysis.Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study.Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patienA Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis.Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients.Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study.Continuous Infusion Versus Intermittent Bolus of Beta-Lactams in Critically Ill Patients with Respiratory Infections: A Systematic Review and Meta-analysis.The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016).Training a Drug to Do New Tricks: Insights on Stability of Meropenem Administered as a Continuous InfusionPharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients
P2860
Q24199096-695CDB9E-7638-4C83-B6A9-34FE289B0647Q26768365-52E36CBF-6AB1-4707-B8CD-215D2B1842ACQ33552161-62633232-CF56-4FE9-BDEC-C1FB2A3A629BQ33753788-F4FAE4A8-71F8-43EC-9437-3FDD8FC3C2E8Q34490565-F46D5032-A595-46E2-8694-0F35F28B7436Q35986250-AB265B7F-FEFB-4907-825E-881AF580B286Q36089167-5DF18180-5E84-4735-A7CF-B07E8641C45FQ36161206-E3BADC3C-5415-4B75-AE22-B9F1BDFD286AQ36329228-E210D578-8D60-4BB1-91CA-0F258CC687CEQ36396195-B28BCE5F-D33D-4FF5-BDAA-AF9BE6BDCC5DQ36633984-5F66006A-AAD1-4596-BB65-D2CAFC424781Q36753909-592AE64C-998A-4BDE-A796-E951FF3F8985Q37563029-5EBD69F8-D54D-4836-8DE9-8E05B6966E43Q37630039-9CA90D80-F55C-4563-9F11-8E8AFBD65833Q37642084-CD8822FF-2557-4002-9C8E-E9B92C0E03A7Q38167345-52EEB720-D4D0-448C-8427-F960195EB521Q38232197-7A8D0EF5-1B72-4CF0-AA9C-FC8BD8F977B0Q38705266-5711197E-D085-488F-8679-3A5B90ACB815Q38714060-BD7E19C9-DD3A-4C54-B530-BE3F250A6FC7Q38896040-66080844-CB57-4EE7-BD23-0C735B84C046Q39586044-C96931A5-0E28-42EE-9457-75C0AEE8596EQ40206253-FE2390B0-EF57-40CF-B32D-46DFB504F23DQ40470332-493019E1-9698-4E9B-9346-32901D42DABEQ40709270-E10244B8-A261-4360-AAFB-662F2E90D4E4Q40727311-36E155B1-86E1-40D2-A7A6-19EA2397D2FEQ42247410-7620A849-E38C-402F-8C34-1B96E8743FCBQ47745708-3ACD1DA7-21A1-47DD-9EF9-42D8F6C1DB20Q50052469-C8349D7F-25E3-4E66-A615-F2C2616F1D9EQ57815074-4C0F0F25-84E5-47A7-B9FD-C795BEB55FCFQ58701649-50B07D94-1C09-4C18-8A84-01A4C74221B3
P2860
Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Clinical and microbiological e ...... d open-label controlled trial.
@ast
Clinical and microbiological e ...... d open-label controlled trial.
@en
type
label
Clinical and microbiological e ...... d open-label controlled trial.
@ast
Clinical and microbiological e ...... d open-label controlled trial.
@en
prefLabel
Clinical and microbiological e ...... d open-label controlled trial.
@ast
Clinical and microbiological e ...... d open-label controlled trial.
@en
P2093
P2860
P356
P1433
P1476
Clinical and microbiological e ...... ed open-label controlled trial
@en
P2093
Alexandra Zidkova
Eduard Kasal
Martin Stepan
Petr Pelnar
Richard Pradl
Tamara Bergerova
P2860
P2888
P356
10.1186/CC11405
P577
2012-06-28T00:00:00Z
P5875
P6179
1010568657